BUY Glenmark Pharmaceuticals — Madhu Bansal, 09 Nov 2026

BUYGlenmark Pharmaceuticals

Glenmark Pharmaceuticals share price target & all analyst calls

byMadhu BansalHorizon: NA (inferred Swing (≤2wk))9 Nov 2026via CNBC Awaaz.

Entry₹2,687.3Inferred

Target₹2,927

Total upside +8.92%

Stop loss₹2,600-3.25% risk

CMP₹2,6401d ago

Active-1.76%+10.87%upside left 8d left

Follow Madhu Bansal for new calls(25% target hit, 56 closed calls)Get alerts Watch GLENMARK for new buy/sell callsGet alerts See 1 other Swing call on GLENMARK See 281 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Nov, 3:41 am IST

4 supporting2 neutral2 opposing

Supports the BUY call (4)

MACD above its signal line — bullish momentum

Technicals · macd·14 Nov · today

Glenmark Pharma shares will react to better-than-expected US sales in Q2, 14% growth in India biz

NewsCnbc-Tv18·6 Nov · 1w ago

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·3 Nov · 2w ago

Glenmark stock: US distribution hub expands supply chain

NewsGoogle News·30 Oct · 2w ago

Neutral / worth noting (2)

Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·5 Nov · 1w ago

Ichnos Glenmark Innovation will present updated clinical data for ISB 2001 at the 68th ASH Annual Meeting.

BSE · Company Update·4 Nov · 1w ago

Weighs against the BUY call (2)

RSI at 84 — overbought territory

Technicals · rsi·14 Nov · today

Glenmark Pharma Q2 Results: Net profit plunges 56% to Rs 264 crore, revenue down at Rs 4,247 cr

NewsEt-Markets·5 Nov · 1w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Madhu Bansal

Every call and its outcome